Premium
Neuroprotective properties of resveratrol and derivatives
Author(s) -
Richard Tristan,
Pawlus Alison D.,
Iglésias MarieLaure,
Pedrot Eric,
WaffoTeguo Pierre,
Mérillon JeanMichel,
Monti JeanPierre
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05865.x
Subject(s) - resveratrol , neuroprotection , in vivo , pharmacology , medicine , parkinson's disease , disease , alzheimer's disease , neuroscience , chemistry , biology , microbiology and biotechnology
Stilbenoid compounds consist of a family of resveratrol derivatives. They have demonstrated promising activities in vitro and in vivo that indicate they may be useful in the prevention of a wide range of pathologies, such as cardiovascular diseases and cancers, as well have anti‐aging effects. More recently stilbenoid compounds have shown promise in the treatment and prevention of neurodegenerative disorders, such as Huntington’s, Parkinson’s, and Alzheimer's diseases. This paper primarily focuses on the impact of stilbenoids in Alzheimer's disease and more specifically on the inhibition of β‐amyloid peptide aggregation.